Pre-Diagnostic Precision Medicine From One Blood Vial – Jim Kean & Robert Fraser | Molecular You скачать в хорошем качестве

Pre-Diagnostic Precision Medicine From One Blood Vial – Jim Kean & Robert Fraser | Molecular You

Jim Kean (CEO) and Robert Fraser (Chief Scientific Officer) present Molecular You’s “pre-diagnostic” platform that goes beyond conventional biomarker panels by measuring proteomics and metabolomics—capturing what’s biologically active, not just symptomatic. Using a small plasma sample, their CLIA/ISO-grade mass-spectrometry workflow quantifies hundreds of markers (288 today, scaling to ~1,000+ next) and maps them into interpretable biological pathways and risk domains (e.g., cardiovascular, cognition/Alzheimer’s, depression, kidney, inflammation, select cancers). They highlight real-world longitudinal detection: a symptom-free stage-1 pancreatic cancer flagged by pathway signatures before standard care would typically catch it, enabling surgery without chemo. The model pairs clear, user-friendly reporting (scores, heat maps, clickable pathways) with actionable plans and optional scientific consults, then scales globally via local market partners (labs, logistics, physician networks) and reimbursement wedges (e.g., predicting immunotherapy adverse events, MRD-style monitoring, dementia stratification). Molecular You positions itself as foundational infrastructure for the global wellness economy—transitioning healthcare from reactive treatment to predictive risk engines for individuals, clinics, employers, insurers, and health systems. About the speakers: Jim Kean is a senior technology executive and entrepreneur focused on simplifying healthcare. He has achieved multiple successful exits in health technology, including founding Sapient Health Network, which became part of WebMD, and WellnessFX, later acquired by Thorne. He also held senior leadership roles at Blue Cross Blue Shield. Rob Fraser, Ph.D., is President and Chief Scientific Officer of Molecular You and its founding CEO. A molecular diagnostics and drug discovery expert, he pioneered low-cost multi-biomarker analytics from a single blood sample. With leadership roles across pharma and biotech, he has co-founded multiple health technology companies and raised over $50 million to advance personalized medicine.